These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 9300703
21. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E, Scarpellino L, Lane P, Acha-Orbea H. Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566 [Abstract] [Full Text] [Related]
22. Antibodies to the C-terminal dipeptide of mouse mammary tumor virus [MMTV(SW)] superantigen effectively inhibit T-cell activation in vivo. Astori M, Karapetian O. J Gen Virol; 1998 Jan; 79 ( Pt 1)():57-60. PubMed ID: 9460923 [Abstract] [Full Text] [Related]
23. Induction and inhibition of CD40-CD40 ligand interactions: a new strategy underlying host-virus relationships. Sharma MD, Leite de Moraes M, Zavala F, Pontoux C, Papiernik M. J Immunol; 1998 Nov 15; 161(10):5357-65. PubMed ID: 9820509 [Abstract] [Full Text] [Related]
25. Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains. Baribaud F, Wirth S, Maillard I, Valsesia S, Acha-Orbea H, Diggelmann H. J Virol; 2001 Aug 15; 75(16):7453-61. PubMed ID: 11462017 [Abstract] [Full Text] [Related]
26. Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. Held W, Shakhov AN, Izui S, Waanders GA, Scarpellino L, MacDonald HR, Acha-Orbea H. J Exp Med; 1993 Feb 01; 177(2):359-66. PubMed ID: 8093892 [Abstract] [Full Text] [Related]
27. Preferential infection of immature dendritic cells and B cells by mouse mammary tumor virus. Vacheron S, Luther SA, Acha-Orbea H. J Immunol; 2002 Apr 01; 168(7):3470-6. PubMed ID: 11907107 [Abstract] [Full Text] [Related]
28. Mouse mammary tumor virus (MMTV), a retrovirus that exploits the immune system. Genetics of susceptibility to MMTV infection. Ross SR, Dzuris JL, Golovkina TV, Clemmons WC, van den Hoogen B. Medicina (B Aires); 1997 Apr 01; 57 Suppl 2():34-42. PubMed ID: 9567342 [Abstract] [Full Text] [Related]
29. Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity. Sugahara D, Tsuji-Kawahara S, Miyazawa M. J Virol; 2004 Jun 01; 78(12):6322-34. PubMed ID: 15163726 [Abstract] [Full Text] [Related]
30. Lack of MMTV superantigen presentation in MHC class II-deficient mice. Beutner U, McLellan B, Kraus E, Huber BT. Cell Immunol; 1996 Mar 15; 168(2):141-7. PubMed ID: 8640859 [Abstract] [Full Text] [Related]
31. A stimulatory Mls-1 superantigen is destroyed by ultraviolet light while other Mtv-7 antigens remain intact. Significance for Mls-1 unresponsiveness. Dannecker G, Mecheri S, Clarke K, Dudhane A, Wang ZQ, Hoffmann MK. J Immunol; 1992 Dec 01; 149(11):3463-7. PubMed ID: 1331237 [Abstract] [Full Text] [Related]
32. A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer. Wang Y, Jiang JD, Xu D, Li Y, Qu C, Holland JF, Pogo BG. Cancer Res; 2004 Jun 15; 64(12):4105-11. PubMed ID: 15205319 [Abstract] [Full Text] [Related]
33. MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus. Held W, Waanders GA, MacDonald HR, Acha-Orbea H. Int Immunol; 1994 Sep 15; 6(9):1403-7. PubMed ID: 7819149 [Abstract] [Full Text] [Related]
34. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ. Proc Natl Acad Sci U S A; 2004 Aug 17; 101(33):12260-5. PubMed ID: 15297622 [Abstract] [Full Text] [Related]
35. Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance. Schirrmacher V, Beutner U, Bucur M, Umansky V, Rocha M, von Hoegen P. J Immunol; 1998 Jul 15; 161(2):563-70. PubMed ID: 9670928 [Abstract] [Full Text] [Related]
37. [Coevolutive mechanisms between retroviruses and their hosts. The murine mammary tumor model]. Nepomnaschy I, Buggiano V, Goldman A, Piazzon I. Medicina (B Aires); 1997 Sep 15; 57(2):235-44. PubMed ID: 9532836 [Abstract] [Full Text] [Related]
38. Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. Ardavin C, Luthi F, Andersson M, Scarpellino L, Martin P, Diggelmann H, Acha-Orbea H. J Virol; 1997 Oct 15; 71(10):7295-9. PubMed ID: 9311805 [Abstract] [Full Text] [Related]
39. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice. Maillard I, Launois P, Himmelrich H, Acha-Orbea H, Diggelmann H, Locksley RM, Louis JA. Eur J Immunol; 2001 Apr 15; 31(4):1288-96. PubMed ID: 11298356 [Abstract] [Full Text] [Related]
40. [Superantigens and retroviral infections. Increase of mammary tumorigenicity due to recombination between exogenous and endogenous MMTV viruses]. Nepomnaschy I, Buggiano V, Goldman A, Deroche A, Bekinschtein P, Berguer P, Piazzon I. Medicina (B Aires); 1997 Apr 15; 57(3):327-31. PubMed ID: 9640768 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]